Nutrition scientist and public health researcher Professor Kerin O'Dea discusses a career dedicated to researching diet and chronic disease in Indigenous Australians. [ + ]

The Australian Society for Microbiology Annual Scientific Meeting & Trade Exhibition returns to Melbourne in 2014. This is the largest and most prestigious microbiology conference held in Australia and attracts approximately 600 microbiologists, allied professionals, researchers and academics from across the country and around the world. [ + ]

dorasVi (ASX:DVL) has entered a partnership with insurer Allianz to recommend the use of ViSafe - a device for measuring movement and muscle activity - for Australian labourers. [ + ]

Miele Professional will distribute Nanosonics' (ASX:NAN) ultrasound probe disinfection system Trophon EPR in the German market. [ + ]

The winners of the 2014 Extreme Imaging Competition were last night announced at the Powerhouse Museum. Now in its third year, the annual event is held by Canon Australia's local research and development arm, Canon Information Systems Research Australia (CiSRA). [ + ]

Patrys (ASX:PAB) has said anticancer candidate PAT-SM6 was found to be safe and potentially effective during a phase I/IIa trial in multiple myeloma. [ + ]

The persistently high blood glucose levels associated with diabetes can, over time, cause damage to blood vessels that result in so-called diabetes-related complications. Preventing or reducing diabetes-related complications in the kidney is the focus of some of the work currently underway at the Baker IDI. [ + ]

Cogstate (ASX:CGS) will supply cognition tests for a phase III trial involving using Eli Lilly's anti-amyloid drug Solanezumab to slow the onset of Alzheimer's disease. [ + ]

Fio Corporation's Deki Reader - a mobile in vitro diagnostic device - has demonstrated consistent interpretation of rapid diagnostic tests (RDTs) for multiple malaria strains in a field evaluation. [ + ]

More than 80% of patients with cutaneous B-cell lymphoma enrolled in a phase II trial of Ascend's in-licensed cancer drug ASN-002 demonstrated a complete or partial response to treatment. [ + ]

Researchers from the BICEP2 collaboration have announced the first direct evidence of cosmic inflation - the rapid expansion of the universe which immediately followed the Big Bang. Until now, the idea of this exponential expansion was just a theory. [ + ]

Researchers from the British Antarctic Survey and the University of Reading have demonstrated for the first time that after over 1500 years frozen in Antarctic ice, moss can come back to life and continue to grow. [ + ]

The FDA has granted Cochlear (ASX:COH) approval to sell the Nucleus Hybrid L24 - a new cochlear implant system designed to address high-frequency hearing loss - in the US. [ + ]

Virax Holdings (ASX:VHL) has arranged to buy Pathway Oncology, a company with an exclusive licence to a cancer drug candidate due to enter phase II trials in breast cancer and multiple myeloma. [ + ]

Imugene (ASX:IMU) has appointed Ground Zero Pharmaceuticals to help the company prepare its Investigational New Drug application with the US FDA for cancer vaccine HER-Vaxx. [ + ]